Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Saka

Showing results (61-70 of 387) with videos related to

Pageof 39
Sort By:
Cancer Research|January 13, 2001
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysisY Ando, H Saka, M Ando, et al.
Arerugi = [Allergy]|November 11, 1999
[Pulmonary aspergillosis as a terminal event in AIDS patient]M Ando, M Hiraiwa, M Kawai, et al.
Applied Microbiology and Biotechnology|November 19, 2002
Development of a membrane dialysis bioreactor and its application to a large-scale culture of a symbiotic bacterium, Symbiobacterium thermophilumK Ueda, H Saka, Yoshiyuki Ishikawa, et al.
British Journal of Cancer|May 4, 2006
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancerR Suzuki, Y Hasegawa, K Baba, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancerM Sato, M Ando, H Minami, et al.
Japanese Journal of Clinical Oncology|November 7, 2001
Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601)S Tsuchiya, Y Ohe, T Sugiura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 2, 2013
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS studyH Yoshioka, I Okamoto, S Morita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
ESMO Open|May 13, 2021
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903K Ito, M Morise, K Wakuda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancerH Yoshioka, N Katakami, H Okamoto, et al.
Pageof 39

Showing results (61-70 of 387) with videos related to

Sort By:
Pageof 39
Cancer Research|January 13, 2001
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysisY Ando, H Saka, M Ando, et al.
Arerugi = [Allergy]|November 11, 1999
[Pulmonary aspergillosis as a terminal event in AIDS patient]M Ando, M Hiraiwa, M Kawai, et al.
Applied Microbiology and Biotechnology|November 19, 2002
Development of a membrane dialysis bioreactor and its application to a large-scale culture of a symbiotic bacterium, Symbiobacterium thermophilumK Ueda, H Saka, Yoshiyuki Ishikawa, et al.
British Journal of Cancer|May 4, 2006
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancerR Suzuki, Y Hasegawa, K Baba, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancerM Sato, M Ando, H Minami, et al.
Japanese Journal of Clinical Oncology|November 7, 2001
Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601)S Tsuchiya, Y Ohe, T Sugiura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 2, 2013
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS studyH Yoshioka, I Okamoto, S Morita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
ESMO Open|May 13, 2021
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903K Ito, M Morise, K Wakuda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancerH Yoshioka, N Katakami, H Okamoto, et al.
Pageof 39